Vident Advisory LLC Purchases Shares of 822 Insulet Corporation $PODD

Vident Advisory LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 822 shares of the medical instruments supplier’s stock, valued at approximately $216,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its position in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. raised its position in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment raised its position in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after purchasing an additional 3,759 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier’s stock valued at $177,096,000 after purchasing an additional 27,408 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier’s stock valued at $1,744,100,000 after purchasing an additional 661,717 shares during the last quarter.

Insulet Stock Down 4.3%

PODD stock opened at $337.61 on Thursday. Insulet Corporation has a twelve month low of $220.10 and a twelve month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $23.76 billion, a PE ratio of 102.62, a price-to-earnings-growth ratio of 2.93 and a beta of 1.36. The business has a 50 day moving average of $310.04 and a 200 day moving average of $291.09.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter last year, the company earned $0.55 EPS. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Raymond James Financial reaffirmed an “outperform” rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 price target for the company. Oppenheimer upped their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Canaccord Genuity Group increased their target price on Insulet from $331.00 to $353.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.